卵母细胞捐献者接种mRNA新冠疫苗是否影响卵巢刺激参数或受者的IVF结局?
这项回顾性多中心队列研究评估了115名卵母细胞捐献者在完成SARS-CoV-2 mRNA疫苗接种前后的卵巢刺激参数,并分析了136个匹配受者周期(其中110例新鲜单胚胎移植)。接种后刺激天数更长、促性腺激素用量更高、获卵数更多,但MII卵数无显著差异,MII/获卵比更偏向接种前;受者受精率、囊胚数、优质囊胚数及生化妊娠和临床妊娠率均无显著差异。结论认为mRNA SARS-CoV-2疫苗对年轻人群卵巢反应无不良影响。
要点
- 接种后刺激天数延长(10.31±1.5 vs 9.51±1.5天,P<0.001),促性腺激素用量更高(2453.5±740 vs 2235.5±615 IU,P<0.001)。
- 接种后获卵数更多(16.62±7.1 vs 15.38±7.0,P=0.02),但MII卵数无显著差异(13.01±6.6 vs 12.61±5.9,P=0.39)。
- MII/获卵比更偏向接种前组(0.83±0.1 vs 0.77±0.2,P=0.019)。
核心结论
- 本研究表明mRNA SARS-CoV-2疫苗对年轻人群的卵巢反应无不良影响。
研究设计与样本
- 回顾性多中心队列研究,纳入2021年11月至2022年2月间至少接受过两次卵巢刺激方案(完成SARS-CoV-2疫苗接种前后各一次)的115名卵母细胞捐献者。
- 分析136个匹配受者周期作为次要结局,其中110名女性接受新鲜单胚胎移植并分析生化β-人绒毛膜促性腺激素浓度及有心跳的临床妊娠率。
主要发现
- 接种后组较接种前组需要更长的刺激时间(10.31±1.5 vs 9.51±1.5天,P<0.001),促性腺激素消耗量更高(2453.5±740 vs 2235.5±615 IU,P<0.001),两组起始剂量相似。
- 接种后组获卵数更多(16.62±7.1 vs 15.38±7.0,P=0.02)。
- 两组MII卵数相似(接种前12.61±5.9 vs 接种后13.01±6.6,P=0.39),MII/获卵比更偏向接种前组(0.83±0.1 vs 接种后0.77±0.2,P=0.019)。
- 在提供卵母细胞数相似的受者中,受精率、获得囊胚总数、优质囊胚数以及生化妊娠率和有心跳的临床妊娠率在两组间无显著差异。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RESEARCH QUESTION: What is the effect of mRNA severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination in young oocyte donors in terms of ovarian response to stimulation, fertilization rate, embryo development and clinical outcomes in recipients? DESIGN: This retrospective, multicentre cohort study evaluated 115 oocyte donors who had undergone at least two ovarian stimulation protocols (before and after complete SARS-CoV-2 vaccination) between November 2021 and February 2022. Comparisons were made of the primary outcomes of days of stimulation, total dose of gonadotrophins and laboratory performance in ovarian stimulation in oocyte donors before and after vaccination. A total of 136 cycles in matched recipients were analysed as secondary outcomes and, from those, 110 women received a fresh single-embryo transfer, with analysis of biochemical β-human chorionic gonadotrophin concentrations and rates of clinical pregnancy with heartbeat. RESULTS: Longer stimulation was required in the post-vaccination than pre-vaccination group (10.31 ± 1.5 versus 9.51 ± 1.5 days; P < 0.001) along with higher gonadotrophin consumption (2453.5 ± 740 versus 2235.5 ± 615 IU; P < 0.001) with a similar starting dose of gonadotrophins in both groups. More oocytes were retrieved in the post-vaccination group (16.62 ± 7.1 versus 15.38 ± 7.0; P = 0.02). However, the number of metaphase II (MII) oocytes was similar between groups (pre-vaccination 12.61 ± 5.9 versus post-vaccination 13.01 ± 6.6; P = 0.39) and the ratio of MII/retrieved oocytes favoured the pre-vaccination group (0.83 ± 0.1 versus 0.77 ± 0.2 post-vaccination; P = 0.019). In recipients with a similar number of provided oocytes, the fertilization rate, total number of obtained blastocysts, number of top-quality blastocysts, and rates of biochemical pregnancy and clinical pregnancy with heartbeat were not significantly different between groups. CONCLUSIONS: This study shows no adverse influence of mRNA SARS-CoV-2 vaccination on ovarian response in a young population.
引用
- Bosch A, Albero S, Castillo JC, et al. Does mRNA COVID-19 vaccination in oocyte donors impact ovarian stimulation parameters or IVF outcomes for recipients? Reprod Biomed Online. 2023. PMID: 36803967. doi:10.1016/j.rbmo.2023.01.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。